Evidence map›Paper›PMID 32626014›Full record

ArticleEFSA journal. European Food Safety Authority2018

Update of the tolerable upper intake level for vitamin D for infants.

EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel), Dominique Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle and 20 more

Open access · diamondAbstract read
In one paragraph

Article in EFSA journal. European Food Safety Authority, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 6 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 6 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Safety of UV-treated oil from yellow mealworm (EFSA journal. European Food Safety Authority · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Guidance on risk-benefit assessment of foods.EFSA journal. European Food Safety Authority · 2024
    Article
  16. Safety of vitamin DEFSA journal. European Food Safety Authority · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 1 institution in 1 country.

EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel)
Dominique Turck
Jean-Louis Bresson
Barbara Burlingame
Tara Dean
Susan Fairweather-Tait
Marina Heinonen
Karen Ildico Hirsch-Ernst
Inge Mangelsdorf
Harry J McArdle
Androniki Naska
Grażyna Nowicka
Kristina Pentieva
Yolanda Sanz
Alfonso Siani
Anders Sjödin
Martin Stern
Daniel Tomé
Henk Van Loveren
Marco Vinceti
Peter Willatts
Mary Fewtrell
Christel Lamberg-Allardt
Hildegard Przyrembel
Davide Arcella
Céline Dumas
Lucia Fabiani
Laura Martino
Daniela Tomcikova
Monika Neuhäuser-Berthold
Lille Inflammation Research International Center · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to revise the tolerable upper intake level (UL) for vitamin D for infants (≤ 1 year) set in 2012. From its literature review, the Panel concluded that the available evidence on daily vitamin D intake and the risk of adverse health outcomes (hypercalciuria, hypercalcaemia, nephrocalcinosis and abnormal growth patterns) cannot be used alone for deriving the UL for infants. The Panel conducted a meta-regression analysis of collected data, to derive a dose-response relationship between daily supplemental intake of vitamin D and mean achieved serum 25(OH)D concentrations. Considering that a serum 25(OH)D concentration of 200 nmol/L or below is unlikely to pose a risk of adverse health outcomes in infants, the Panel estimated the percentage of infants reaching a concentration above this value at different intakes of vitamin D. Based on the overall evidence, the Panel kept the UL of 25 μg/day for infants aged up to 6 months and set a UL of 35 μg/day for infants 6-12 months. The Panel was also asked to advise on the safety of the consumption of infant formulae with an increased maximum vitamin D content of 3 μg/100 kcal (Commission Delegated Regulation (EU) 2016/127 repealing Directive 2006/141/EC in 2020). For infants aged up to 4 months, the intake assessment showed that the use of infant formulae containing vitamin D at 3 μg/100 kcal may lead some infants to receive an intake above the UL of 25 μg/day from formulae alone without considering vitamin D supplemental intake. For infants aged 4-12 months, the 95th percentile of vitamin D intake (high consumers) estimated from formulae and foods fortified or not with vitamin D does not exceed the ULs, without considering vitamin D supplemental intake.

Indexed as

25(OH)Dadverse health outcomesinfantsintakeULvitamin D

Identifiers

PMID32626014
PMCPMC7009676
OpenAlexW2886180191

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.